ENSC Stock Overview
A clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Ensysce Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.68 |
| 52 Week High | US$2.65 |
| 52 Week Low | US$0.51 |
| Beta | 0.80 |
| 1 Month Change | 19.09% |
| 3 Month Change | -26.88% |
| 1 Year Change | -73.54% |
| 3 Year Change | -99.98% |
| 5 Year Change | -99.97% |
| Change since IPO | -99.97% |
Recent News & Updates
Shareholder Returns
| ENSC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 22.4% | 0.7% | 1.2% |
| 1Y | -73.5% | 5.0% | 27.7% |
Return vs Industry: ENSC underperformed the US Biotechs industry which returned 5.8% over the past year.
Return vs Market: ENSC underperformed the US Market which returned 26% over the past year.
Price Volatility
| ENSC volatility | |
|---|---|
| ENSC Average Weekly Movement | 11.6% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ENSC's share price has been volatile over the past 3 months.
Volatility Over Time: ENSC's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 7 | D. Kirkpatrick | www.ensysce.com |
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis.
Ensysce Biosciences, Inc. Fundamentals Summary
| ENSC fundamental statistics | |
|---|---|
| Market cap | US$5.61m |
| Earnings (TTM) | -US$11.55m |
| Revenue (TTM) | US$1.75m |
3.0x
P/S Ratio-0.4x
P/E RatioIs ENSC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENSC income statement (TTM) | |
|---|---|
| Revenue | US$1.75m |
| Cost of Revenue | US$7.59m |
| Gross Profit | -US$5.84m |
| Other Expenses | US$5.71m |
| Earnings | -US$11.55m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.52 |
| Gross Margin | -334.41% |
| Net Profit Margin | -661.09% |
| Debt/Equity Ratio | 7.2% |
How did ENSC perform over the long term?
See historical performance and comparison